Table 3.
Association of statin use with primary and secondary endpoints, stratified by the type of the co-administered calcineurin inhibitor
| Endpoint | Calcineurin inhibitor | P | ||||
|---|---|---|---|---|---|---|
| Cyclosporine | Tacrolimus | |||||
| Studies no. | RR (95% CI) | Studies no. | RR (95% CI) | |||
| MACE | 3 | 1.46 (0.38–5.60) | 2 | 0.52 (0.14–1.88) | 0.344 | |
| Mortality | 3 | 0.96 (0.89–1.03) | 9 | 0.82 (0.67-1.00) | 0.393 | |
| Graft loss | 7 | 0.83 (0.43–1.58) | 1 | 0.98 (0.82–1.18) | 0.812 | |
| Hepatotoxicity | 4 | 0.64 (0.44–0.92) * | 1 | 0.84 (0.72–0.98) * | 0.178 | |
| Creatine kinase elevation | 3 | 1.17 (0.56–2.42) | 0 | - | NA | |
| Rhabdomyolysis | 2 | 1.09 (0.57–2.10) | 1 | 1.41 (1.10–1.81) * | 0.478 | |
| Diabetes mellitus | 1 | 1.11 (0.89–1.37) | 1 | 1.13 (1.07–1.20) * | NA | |
| Cataract | 1 | 1.22 (0.93–1.62) | 1 | 1.22 (1.14–1.31) * | NA | |
| Hip fracture | 1 | 3.00 (0.13–69.5) | 0 | - | NA | |
| Venous thromboembolism | 0 | - | 1 | 0.92 (0.39–2.19) | NA | |
| Cancer | 1 | 0.94 (0.82–1.07) | 0 | - | NA | |
Asterisks denote statistically significant results. P-values correspond to the significance of the interaction between the type of calcineurin inhibitor and statin effects
RR: relative risk; CI: confidence intervals; NA: not applicable